Aerie Pharmaceuticals Company Profile (NASDAQ:AERI)

About Aerie Pharmaceuticals (NASDAQ:AERI)

Aerie Pharmaceuticals logoAerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company's product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company's product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AERI
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.03781 billion
  • Outstanding Shares: 33,634,000
Average Prices:
  • 50 Day Moving Avg: $53.99
  • 200 Day Moving Avg: $46.83
  • 52 Week Range: $16.61 - $59.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -21.52
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $2.50 per share
  • Price / Book: 22.38
  • EBIDTA: ($99,150,000.00)
  • Return on Equity: -136.01%
  • Return on Assets: -47.53%
  • Debt-to-Equity Ratio: 1.47%
  • Current Ratio: 15.50%
  • Quick Ratio: 15.50%
  • Average Volume: 601,459 shs.
  • Beta: 1.16
  • Short Ratio: 5.93
Frequently Asked Questions for Aerie Pharmaceuticals (NASDAQ:AERI)

What is Aerie Pharmaceuticals' stock symbol?

Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) announced its earnings results on Tuesday, May, 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.02. View Aerie Pharmaceuticals' Earnings History.

When will Aerie Pharmaceuticals make its next earnings announcement?

Aerie Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Aerie Pharmaceuticals.

Where is Aerie Pharmaceuticals' stock going? Where will Aerie Pharmaceuticals' stock price be in 2017?

12 equities research analysts have issued 12 month target prices for Aerie Pharmaceuticals' stock. Their forecasts range from $48.00 to $100.00. On average, they expect Aerie Pharmaceuticals' share price to reach $65.67 in the next twelve months. View Analyst Ratings for Aerie Pharmaceuticals.

What are analysts saying about Aerie Pharmaceuticals stock?

Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Aerie’s efforts on developing two late-stage candidates – Rhopressa and Roclatan – are encouraging. The company resubmitted new drug application (NDA) for lead candidate Rhopressa in Feb 2017. The FDA determined that the application is sufficiently complete to permit a substantive review and set the PDUFA goal date for the completion of review as Feb 28, 2018. Aerie had earlier withdrawn its NDA that was filed in September as a third party manufacturing facility in Tampa, FL was not ready for pre-approval inspection by the FDA. A potential approval and successful commercialization will significantly boost the company’s growth prospects in the global ophthalmic market. The recent data on Roclatan is also positive. Moreover, Aerie’s shares have outperformed the industry in the year so far. However, with no approved product in its portfolio, Aerie depends heavily on a potential approval of Rhopressa." (7/24/2017)
  • 2. HC Wainwright analysts commented, "Blueprint reported a Q1 net loss of $28MM and ended the quarter with $452MM." (5/3/2017)
  • 3. Aegis analysts commented, "We still consider the upcoming Mercury 2 three-month efficacy readout for Roclatan expected before the end of Q2, 2017 as being a potentially share moving event. Higher patients dropout rate seen in Rhopressa arm relative to Timolol arm is not concerning to us. 30% of the patients in the Rhopressa arm of the trial discontinued treatment by month 6 compared to 12% of the patient population in the Timolol arm. The most common reason for discontinuation seen in the Rhopressa arm was related to adverse events, at about 19.4%. 2.2% (8) of the subjects in the Timolol arm dropped out due to adverse events. As a point of reference, given that 47% of patients (118 out of 251 patients) on Rhopressa QD completed the treatment by month 12 in Rocket 2, we estimate a maximum drop-off rate of Rhopressa at 53%. Further, according to results published in Persistency: A New Take on Patient Care" by Schwartz in Review of Ophthalmology 11.4 (2004): 108, the discontinuation rates of 66%/50%/46% for Latanoprost/Travoprost/Bimatoprost were seen at month 3 and 6, with rates increasing to 67%/81%/81%, respectively, at month 12." (4/13/2017)
  • 4. Needham & Company LLC analysts commented, " AERI reported 4Q16 financials and updated ongoing Rhopressa and Roclatan development activities. The Rhopressa NDA was refiled in late Feb following an issue at the third party manufacturer. AERI expects a potential PDUFA in 1Q18 after a standard FDA review and is in the process of building a commercial org in anticipation of a 1H18 product launch. Key data from both Rhopressa and Roclatan are expected in 2Q17: top-line safety data from the ph 3 ROCKET-4 trial and top-line efficacy data from the ph 3 MERCURY-2 trial. AERI expects to file an NDA for Roclatan in late 2017/early 2018. We maintain our Buy rating and slightly adjust our $PT to $58 (from $52) to reflect a model and valuation update." (3/8/2017)
  • 5. Brean Capital analysts commented, "At yesterday’s investor day, Aerie painted a clearer portrait of the current standard of care and competitive glaucoma treatment environment. Management also provided further insight into the recent Mercury 1 data for Roclatan, a closer look at how to measure the effectiveness of glaucoma treatment with added perspective from a former physician, as well as revisited what the company’s future value adding drivers will be and articulated the international strategy. We took the opportunity to dive deeper into our model, taking into account potential future European launches and Japanese clinical trials." (10/6/2016)

Who are some of Aerie Pharmaceuticals' key competitors?

Who are Aerie Pharmaceuticals' key executives?

Aerie Pharmaceuticals' management team includes the folowing people:

  • Vicente Anido Jr., Ph.D., Chairman of the Board, Chief Executive Officer
  • Thomas A. Mitro, President, Chief Operating Officer
  • Casey C. Kopczynski Ph.D., Co-Founder, Chief Scientific Officer
  • Richard J. Rubino CPA, Chief Financial Officer, Secretary
  • Gerald D. Cagle Ph.D., Independent Director
  • Richard J. Croarkin, Independent Director
  • Michael M. Du Toit, Independent Director
  • Murray A. Goldberg, Independent Director
  • Benjamin F. McGraw III, Pharm.D., Independent Director

Who owns Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (0.69%), Handelsbanken Fonder AB (0.39%), Handelsinvest Investeringsforvaltning (0.13%), Legato Capital Management LLC (0.12%), Harvey Capital Management Inc. (0.08%) and Fox Run Management L.L.C. (0.04%). Company insiders that own Aerie Pharmaceuticals stock include Foresite Capital Fund Ii, LP, Geoffrey M Duyk and Gerald D Cagle. View Institutional Ownership Trends for Aerie Pharmaceuticals.

Who sold Aerie Pharmaceuticals stock? Who is selling Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Harvey Capital Management Inc. and Creative Planning. Company insiders that have sold Aerie Pharmaceuticals stock in the last year include Foresite Capital Fund Ii, LP and Geoffrey M Duyk. View Insider Buying and Selling for Aerie Pharmaceuticals.

Who bought Aerie Pharmaceuticals stock? Who is buying Aerie Pharmaceuticals stock?

Aerie Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Handelsbanken Fonder AB, Handelsinvest Investeringsforvaltning, Legato Capital Management LLC, Fox Run Management L.L.C. and Aperio Group LLC. Company insiders that have bought Aerie Pharmaceuticals stock in the last two years include Foresite Capital Fund Ii, LP and Gerald D Cagle. View Insider Buying and Selling for Aerie Pharmaceuticals.

How do I buy Aerie Pharmaceuticals stock?

Shares of Aerie Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aerie Pharmaceuticals' stock price today?

One share of Aerie Pharmaceuticals stock can currently be purchased for approximately $55.95.

MarketBeat Community Rating for Aerie Pharmaceuticals (NASDAQ AERI)
Community Ranking:  4.2 out of 5 (   )
Outperform Votes:  361 (Vote Outperform)
Underperform Votes:  68 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Aerie Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Aerie Pharmaceuticals (NASDAQ:AERI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.92)
Consensus Price Target: $65.67 (17.37% upside)

Analysts' Ratings History for Aerie Pharmaceuticals (NASDAQ:AERI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/20/2017Cantor FitzgeraldReiterated RatingOverweight -> Overweight$56.00 -> $62.00HighView Rating Details
7/4/2017Stifel NicolausBoost Price TargetBuy$55.00 -> $65.00MediumView Rating Details
7/3/2017Canaccord GenuityReiterated RatingBuy$65.00MediumView Rating Details
5/26/2017Cowen and CompanySet Price TargetBuy$100.00N/AView Rating Details
5/25/2017AegisBoost Price TargetBuy$63.00 -> $70.00HighView Rating Details
5/25/2017HC WainwrightReiterated RatingBuy$69.00HighView Rating Details
5/25/2017Needham & Company LLCBoost Price TargetBuy -> Buy$58.00 -> $65.00HighView Rating Details
3/31/2017JMP SecuritiesReiterated RatingOutperform$57.00LowView Rating Details
3/9/2017Raymond James Financial, Inc.DowngradeStrong-Buy -> Market Perform$48.00LowView Rating Details
3/8/2017Royal Bank Of CanadaBoost Price TargetOutperform$54.00 -> $55.00MediumView Rating Details
2/17/2017Roth CapitalInitiated CoverageBuy$69.00N/AView Rating Details
10/6/2016Brean CapitalReiterated RatingBuy$48.00 -> $63.00N/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Aerie Pharmaceuticals (NASDAQ:AERI)
Earnings by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Earnings History by Quarter for Aerie Pharmaceuticals (NASDAQ AERI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/1/2017($0.62)N/AView Earnings Details
5/2/2017Q1 2017($0.74)($0.76)ViewListenView Earnings Details
3/7/2017Q4 2016($0.67)($0.87)ViewListenView Earnings Details
11/2/2016Q316($0.70)($0.67)ViewN/AView Earnings Details
8/3/2016Q216($0.74)($0.72)ViewN/AView Earnings Details
5/2/2016Q116($0.64)($0.72)ViewN/AView Earnings Details
3/1/2016Q415($0.72)($0.64)ViewN/AView Earnings Details
11/3/2015Q315($0.66)($0.69)ViewN/AView Earnings Details
8/5/2015Q215($0.70)($0.73)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.62)($0.70)ViewListenView Earnings Details
3/2/2015Q414($0.51)($0.69)ViewN/AView Earnings Details
11/11/2014Q3 2014($0.40)($0.54)ViewN/AView Earnings Details
8/6/2014Q2 2014($0.37)($0.49)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.35)($0.28)ViewN/AView Earnings Details
3/18/2014Q413($0.25)($0.62)ViewN/AView Earnings Details
12/4/2013Q313($0.25)($10.81)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)
Current Year EPS Consensus Estimate: $-3.13 EPS
Next Year EPS Consensus Estimate: $-2.6 EPS


Dividend History for Aerie Pharmaceuticals (NASDAQ:AERI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Aerie Pharmaceuticals (NASDAQ:AERI)
Insider Ownership Percentage: 9.36%
Institutional Ownership Percentage: 92.01%
Insider Trades by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Insider Trades by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2017Foresite Capital Fund Ii, L.P.Major ShareholderSell20,000$55.95$1,119,000.00View SEC Filing  
4/19/2017Gerald D CagleDirectorBuy2,000$41.70$83,400.00View SEC Filing  
2/15/2017Geoffrey M DuykDirectorSell41,591$46.63$1,939,388.33View SEC Filing  
10/6/2016Foresite Capital Fund Ii, L.P.Major ShareholderSell50,000$40.34$2,017,000.00View SEC Filing  
7/22/2016Foresite Capital Fund Ii, L.P.Major ShareholderBuy250,000$17.50$4,375,000.00View SEC Filing  
4/15/2015Anand MehraDirectorSell425,000$33.64$14,297,000.00View SEC Filing  
1/8/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell175,000$31.11$5,444,250.00View SEC Filing  
1/5/2015Lifesciences Ii L.P. ClarusMajor ShareholderSell23,620$30.86$728,913.20View SEC Filing  
12/29/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell80,724$30.05$2,425,756.20View SEC Filing  
12/23/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,704$30.36$1,509,013.44View SEC Filing  
12/22/2014Lifesciences Ii L.P. ClarusMajor ShareholderSell49,441$30.36$1,501,028.76View SEC Filing  
11/25/2014Anand MehraDirectorSell800,000$26.00$20,800,000.00View SEC Filing  
11/25/2014Group Holdings (Sbs) Advis TpgInsiderSell1,300,000$25.97$33,761,000.00View SEC Filing  
7/10/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell1,000,000$25.17$25,170,000.00View SEC Filing  
7/9/2014Group Holdings (Sbs) Advis TpgMajor ShareholderSell500,000$25.05$12,525,000.00View SEC Filing  
5/22/2014Anand MehraDirectorSell323,932$16.00$5,182,912.00View SEC Filing  
5/22/2014Iv L.P. AcpMajor ShareholderSell300,000$16.00$4,800,000.00View SEC Filing  
5/16/2014Gerald CagleDirectorBuy1,854$15.07$27,939.78View SEC Filing  
10/30/2013Brian LevyInsiderBuy6,000$10.00$60,000.00View SEC Filing  
10/30/2013Iv L.P. AcpMajor ShareholderBuy110,000$10.00$1,100,000.00View SEC Filing  
10/30/2013Richard J RubinoCFOBuy10,000$10.00$100,000.00View SEC Filing  
10/30/2013Thomas A MitroCOOBuy5,000$10.00$50,000.00View SEC Filing  
10/30/2013Vicente Anido JrCEOBuy28,000$10.00$280,000.00View SEC Filing  
10/25/2013Anand MehraDirectorBuy285,000$10.00$2,850,000.00View SEC Filing  
10/25/2013Lifesciences Ii L.P. ClarusMajor ShareholderBuy321,000$10.00$3,210,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aerie Pharmaceuticals (NASDAQ:AERI)
Latest Headlines for Aerie Pharmaceuticals (NASDAQ:AERI)
DateHeadline logoAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Given Consensus Rating of "Buy" by Brokerages - July 25 at 4:51 PM logoAerie Pharmaceuticals Announces Appointment of Richard A. Halprin as Director of Professional Affairs - Business Wire (press release) - July 25 at 3:24 PM logoAerie Pharmaceuticals, Inc. (AERI) to Release Earnings on Tuesday - July 25 at 7:06 AM logoZacks: Brokerages Expect Aerie Pharmaceuticals Inc (AERI) to Post -$0.84 EPS - July 25 at 12:26 AM logoDiabetic Macular Edema Pipeline Therapeutics Companies and Drugs Profile Insights 2017 Available at RnR Market ... - PR Newswire (press release) - July 24 at 1:44 PM logoAerie Pharmaceuticals, Inc. (NASDAQ:AERI) to Post FY2017 Earnings of ($2.99) Per Share, Cantor Fitzgerald Forecasts - July 24 at 8:49 AM logoCommit To Purchase Aerie Pharmaceuticals At $40, Earn 13% Using Options - Nasdaq - July 21 at 4:51 PM logoInsmed (INSM) versus Aerie Pharmaceuticals (AERI) Head to Head Survey - July 21 at 2:26 PM logoBRIEF-Aerie Pharmaceuticals reports positive Roclatan phase 3 12-month topline safety results - July 21 at 2:59 AM logoAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Price Target Raised to $62.00 at Cantor Fitzgerald - July 20 at 8:23 PM logoAerie Pharma's eye drop Roclatan safe in 12-month study - Seeking Alpha - July 19 at 10:08 PM logoBRIEF-Brian Grossman reports 6.3 pct passive stake in Aerie Pharmaceuticals Inc as of July 5 - SEC filing - July 18 at 4:13 PM logoAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Downgraded by Zacks Investment Research to Hold - July 11 at 10:14 PM logoInotek to explore strategic options after eye drug fails trial - Reuters - July 8 at 3:15 PM logoInotek to explore strategic options after eye drug fails trial - July 8 at 8:11 AM logoAerie Pharmaceuticals, Inc. (NASDAQ:AERI) Earns Buy Rating from Canaccord Genuity - July 3 at 9:02 AM logoAerie Pharmaceuticals, Inc. (AERI) Receives Average Rating of "Buy" from Analysts - June 30 at 12:44 PM logo Brokerages Expect Aerie Pharmaceuticals, Inc. (AERI) Will Announce Earnings of -$0.84 Per Share - June 28 at 8:16 PM logoBidaskClub Lowers Aerie Pharmaceuticals, Inc. (AERI) to Strong Sell - June 17 at 7:52 PM logoCan The Uptrend Continue for Aerie Pharmaceuticals (AERI)? - Nasdaq - June 7 at 3:25 PM logoAerie Pharmaceuticals Inc (AERI) Given Consensus Rating of "Buy" by Analysts - June 5 at 11:11 AM logoZacks: Brokerages Anticipate Aerie Pharmaceuticals Inc (AERI) Will Post Earnings of -$0.84 Per Share - June 2 at 6:42 PM logoAerie Pharmaceuticals Inc (AERI) Major Shareholder Foresite Capital Fund Ii, L.P. Sells 20,000 Shares - May 31 at 10:28 PM logoI've Joined Aerie Pharmaceuticals In Selling Its Stock - Seeking Alpha - May 31 at 3:23 PM logoAerie Pharmaceuticals' (AERI) "Buy" Rating Reiterated at Stifel Nicolaus - May 27 at 12:08 PM logoAerie Pharmaceuticals Inc (AERI) Given a $100.00 Price Target by Cowen and Company Analysts - May 27 at 8:24 AM logoAerie Pharmaceuticals Raises $125 Million in ATM Sales and Upsized Follow-On Offering - Business Wire (press release) - May 26 at 8:38 PM logoAerie Pharmaceuticals Raises $125 Million in ATM Sales and Upsized Follow-On Offering - May 26 at 3:32 PM logoBioCryst and Aerie Pharmaceuticals' Shares Swell on Positive Study Results - May 26 at 3:32 PM logoPharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data - May 26 at 3:32 PM logoBiotech Movers: Immunomedics, Aerie, Exelixis - May 26 at 3:32 PM logoBRIEF-Aerie Pharma to offer common shares in public offering - May 26 at 1:55 AM logoAegis Reaffirms "Buy" Rating for Aerie Pharmaceuticals Inc (AERI) - May 26 at 12:58 AM logoAerie Pharmaceuticals Inc (AERI) Given Outperform Rating at Cowen and Company - May 26 at 12:23 AM logoBRIEF-Aerie Pharmaceuticals enters into controlled equity offering sales agreement with Cantor Fitzgerald - Reuters - May 25 at 8:47 PM logoAerie Pharma stock surges 32% on positive late-stage trial results for glaucoma eye drops - MarketWatch - May 25 at 8:47 PM logoWhy Aerie Pharmaceuticals Inc. Is Skyrocketing Today - Motley Fool - May 25 at 8:47 PM logoAerie Pharmaceuticals Inc (AERI) Given a $69.00 Price Target at HC Wainwright - May 25 at 8:36 PM logoAerie Pharmaceuticals Inc (AERI) Given a $56.00 Price Target at Cantor Fitzgerald - May 25 at 4:56 PM logoBRIEF-Aerie Pharma's Roclatan succeeds in second late-stage study - May 25 at 3:44 PM logoAerie Pharmaceuticals (AERI) Updates On Roclatan Mercury Phase 3 Topline Efficacy Results - Slideshow - May 25 at 3:44 PM logoHas Aerie Pharma Put The 'Binary Boogeyman' To Bed With Roclatan Phase 3 Data? - May 25 at 3:23 PM logoWhy Aerie Pharmaceuticals Inc. Is Skyrocketing Today - May 25 at 1:26 PM logoNeedham & Company LLC Boosts Aerie Pharmaceuticals Inc (AERI) Price Target to $65.00 - May 25 at 11:28 AM logoAerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase ... - Business Wire (press release) - May 25 at 1:24 AM logoAerie Pharmaceuticals Inc. (AERI) Is Surging On Phase 3 Study Results - May 24 at 8:23 PM logoAerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 Topline Efficacy Results - May 24 at 8:23 PM logoAerie Pharma stock surges 32% on positive late-stage trial results for glaucoma eye drops - May 24 at 8:23 PM logoCanaccord Genuity Analysts Give Aerie Pharmaceuticals Inc (AERI) a $56.00 Price Target - May 23 at 9:58 PM logoImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher - May 19 at 9:43 AM



Aerie Pharmaceuticals (AERI) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff